SELLAS Life Sciences (SLS) Times Interest Earned (2011 - 2026)
SELLAS Life Sciences (SLS) posted quarterly Times Interest Earned of -$1.59 for Q1 2026, up 94.74% year-over-year from -$0.82 in Q1 2025, and up 98.07% quarter-over-quarter from -$82.55 in Q4 2025.
SELLAS Life Sciences (SLS) Times Interest Earned (2011 - 2026) Analysis & Trends
SELLAS Life Sciences (SLS) has reported Times Interest Earned for 14 consecutive years, with -$1.59 the latest figure, recorded in Q1 2026.
- In Q1 2026, Times Interest Earned rose 94.74% year-over-year to -$1.59; the TTM figure through Mar 2026 stood at -$5.42 (up 90.29% YoY), while the FY2025 annual figure was -$1.24, up 18.03% from the prior year.
- Times Interest Earned grew to -$1.59 in Q1 2026 per SLS's latest filing, from -$82.55 in the prior quarter.
- Across five years, Times Interest Earned topped out at -$1.59 in Q1 2026 and bottomed at -$167.35 in Q1 2022.
- Historically, Times Interest Earned has averaged -$71.72 across 5 years, with a median of -$76.21 in 2024.
- Annual changes were most pronounced in 2022 — Times Interest Earned tumbled 645.43% — and 2025, when it surged 95.61%.
- SELLAS Life Sciences' Times Interest Earned stood at -$47.23 in 2022, then sank by 73.13% to -$81.77 in 2023, then rose by 15.4% to -$69.18 in 2024, then retreated by 19.33% to -$82.55 in 2025, then surged by 98.07% to -$1.59 in 2026.
- Business Quant data shows SLS's Times Interest Earned at -$1.59 in Q1 2026, -$82.55 in Q4 2025, and -$35.42 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | SELLAS Life Sciences | 2.32 Bn | 2.18 Bn | - | -0.33 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -0.33 |
| Mar 31, 2026 | -1.59 |
| Dec 31, 2025 | -82.55 |
| Sep 30, 2025 | -35.42 |
| Jun 30, 2025 | -3.34 |
| Mar 31, 2025 | -30.32 |
| Dec 31, 2024 | -69.18 |
| Sep 30, 2024 | -73.29 |
| Jun 30, 2024 | -76.21 |
| Mar 31, 2024 | -96.45 |
| Dec 31, 2023 | -81.77 |
| Sep 30, 2023 | -93.61 |
| Jun 30, 2023 | -90.50 |
| Mar 31, 2023 | -112.81 |
| Dec 31, 2022 | -47.23 |
| Sep 30, 2022 | -71.46 |
| Jun 30, 2022 | -86.23 |
| Mar 31, 2022 | -167.35 |
| Dec 31, 2021 | -116.19 |
| Sep 30, 2021 | -69.77 |